Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage

US10570100B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10570100-B2
Application numberUS-201615740787-A
CountryUS
Kind codeB2
Filing dateJul 7, 2016
Priority dateJul 8, 2015
Publication dateFeb 25, 2020
Grant dateFeb 25, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of Formula (I): or a tautomer thereof, or a deuterium isotope of each of the above wherein up to 10 hydrogen atoms that are attached to one or more carbon atoms are replaced with deuterium(s), or a pharmaceutically acceptable salt of each of the foregoing, or a pharmaceutically acceptable solvate of each of the above mentioned, wherein A is selected from L 1 is —(CH 2 ) q —, wherein one or more hydrogens are optionally substituted with C 1 -C 3 alkyl and/or at least two or more vicinal hydrogens are optionally substituted with an optionally substituted 3-5 membered heterocyclyl or an optionally substituted 3-5 membered cycloalkyl; and wherein q is 3, 4, 5, 6, 7, or 8; or wherein one or more hydrogens are optionally substituted with C 1 -C 3 alkyl and/or at least two or more vicinal hydrogens are optionally substituted with an optionally substituted 3-5 membered heterocyclyl or an optionally substituted 3-5 membered cycloalkyl; and wherein p is 0, 1, 2, 3, 4, or 5 and z is 0, 1, 2, 3, 4, or 5; or —(CH 2 ) m -X 15 —(CH 2 ) n —, wherein one or more hydrogens are optionally substituted with C 1 -C 3 alkyl and/or at least two or more vicinal hydrogens are optionally substituted with an optionally substituted 3-5 membered heterocyclyl or an optionally substituted 3-5 membered cycloalkyl; and wherein m is 0, 1, 2, or 3 and n is 3, 4, 5, 6, or 7; or wherein one or more hydrogens are optionally substituted with C 1 -C 3 alkyl and/or at least two or more vicinal hydrogens are optionally substituted with an optionally substituted 3-5 membered heterocyclyl or an optionally substituted 3-5 membered cycloalkyl; and wherein o is 0, 1, 2, or 3; r is 1, 2 or 3; and s is 0, 1, 2, 3, or 4; and wherein X 15 is NR 40 , O, or S, wherein R 40 is H or C 1 -C 3 alkyl; L 2 is —SO 2 NR 50 —, wherein the sulfur is attached to L 1 ; —NR 50 SO 2 —, wherein the nitrogen is attached to L 1 ; —C(O)NR 50 —, wherein the carbon is attached to L 1 ; —NR 50 C(O)—, wherein the nitrogen is attached to L 1 ; —NR 50 SO 2 NR 50 —; or -NR 50 CONR 50 —; each R 50 independently is hydrogen, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 2 -C 6 heteroalkyl, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 3 -C 6 heteroalkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 6 heteroalkynyl, or Z; Z is each R 51 and R 52 independently is hydrogen or an optionally substituted C 1 -C 10 alkyl; X is an optionally substituted hydroxy group, an optionally substituted NH 2 group, or an optionally substituted SH group; and B is selected from the group consisting of: wherein each R 6 independently is hydrogen, an optionally substituted C 1 -C 6 alkoxy, or halo; each R 7 independently is an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 3 -C 10 heteroaryl, an optionally substituted C 3 -C 10 heterocyclyl, or an optionally substituted C 6 -C 10 aryl; or R 6 and R 7 together with the atoms they are attached to form an optionally substituted 5-7 membered ring; or 2 R 6 groups together with the atoms they are attached to form an optionally substituted 5-7 membered ring; each R 61 and R 62 is independently N or CH, provided that at least one of R 61 and R 62 is N, each R 63 is independently NR 90 , S, or O; each R 64 is independently N or CH; each R 90 is independently hydrogen or R 7 ; each R 1 -R 3 independently is H, halo, an optionally substituted C 1 -C 6 alkyl, an optionally substituted 4-15 membered heterocyclyl, or —OR 20 or, if two of R 1 -R 3 are on adjacent carbon atoms, then two such substituents together with the atoms they are attached to form an optionally substituted 5-7 membered ring; R 20 is (CH 2 ) w —R 21 , an optionally substituted C 3 -C 6 cycloalkyl, or an optionally substituted C 1 -C 6 alkyl; R 21 is an optionally substituted C 1 -C 10 alkyl, an optionally substituted C 2 -C 10 alkenyl, an optionally substituted C 2 -C 10 alkynyl, an optionally substituted C 3 -C 6 cycloalkyl, an optionally substituted C 6 -C 10 aryl, an optionally substituted 5-15 membered heteroaryl, an optionally substituted 4-15 membered heterocyclyl, or wherein each R 22 -R 24 independently is an optionally substituted C 1 -C 3 alkyl or hydroxy; or two of R 22 -R 24 together with the carbon atoms they are attached to form a 3-7 membered ring; and w is 1, 2, 3, 4, or 5. 2. The compound of claim 1 , wherein B is wherein R 1 , R 2 , and R 3 are as defined above as in claim 1 ; or R 1 is H, and R 2 and R 3 are as defined above as in claim 1 ; or R 3 is H or —OR 20 , and R 1 and R 2 are as defined above as in claim 1 ; or R 2 is F or H, and R 1 and R 3 are as defined above as in claim 1 ; or R 1 and R 2 together with the atoms they are attached to form an optionally substituted 5-7 membered ring; or R 2 and R 3 together with the atoms they are attached to form an optionally substituted 5-7 membered ring. 3. The compound of claim 1 , wherein L 1 is selected from the group consisting of: and optionally substituted versions thereof wherein 1-5 hydrogen atoms are optionally substituted, wherein R 70 is an optionally substituted C 1 -C 3 alkyl, and wherein the left side of the moieties are attached to A. 4. The compound of claim 1 , wherein L 2 is —NHS(O) 2 — wherein the nitrogen is attached to L 1 . 5. The compound of claim 1 , wherein B is wherein R 20 is (CH 2 ) w —R 21 , an optionally substituted C 3 -C 6 cycloalkyl, or an optionally substituted C 1 -C 6 alkyl; R 21 is an optionally substituted C 1 -C 10 alkyl, an optionally substituted C 2 -C 10 alkenyl, an optionally substituted C 2 -C 10 alkynyl, an optionally substituted C 3 -C 6 cycloalkyl, an optionally substituted C 6 -C 10 aryl, an optionally substituted 5-15 membered heteroaryl, an optionally substituted 4-15 membered heterocyclyl, or wherein each R 22 -R 24 independently is an optionally substituted C 1 -C 3 alkyl or hydroxy; or two of R 22 -R 24 together with

Assignees

Inventors

Classifications

  • C07D241/08Primary

    with oxygen atoms directly attached to ring carbon atoms · CPC title

  • 2,5-Pyrrolidine-diones · CPC title

  • with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members · CPC title

  • Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals · CPC title

  • attached in positions 2 and 6, e.g. glutarimide · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10570100B2 cover?
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
Who is the assignee on this patent?
Univ Southern California, Cv6 Therapeutics Ni Ltd
What technology area does this patent fall under?
Primary CPC classification C07D241/08. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).